Literature DB >> 23751402

Knowledge and practice related to compliance with mass drug administration during the Egyptian national filariasis elimination program.

Khaled M Abd Elaziz1, Maged El-Setouhy, Mark H Bradley, Reda M R Ramzy, Gary J Weil.   

Abstract

Lymphatic filariasis (LF) has been targeted for global elimination by 2020. The primary tool for the program is mass drug administration (MDA) with antifilarial medications to reduce the source of microfilariae required for mosquito transmission of the parasite. This strategy requires high MDA compliance rates. Egypt initiated a national filariasis elimination program in 2000 that targeted approximately 2.7 million persons in 181 disease-endemic localities. This study assessed factors associated with MDA compliance in year three of the Egyptian LF elimination program. 2,859 subjects were interviewed in six villages. The surveyed compliance rate for MDA in these villages was 85.3% (95% confidence interval = 83.9-86.5%). Compliance with MDA was positively associated with LF knowledge scores, male sex, and older age. Adverse events reported by 18.4% of participants were mild and more common in females. This study has provided new information on factors associated with MDA compliance during Egypt's successful LF elimination program.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23751402      PMCID: PMC3741246          DOI: 10.4269/ajtmh.12-0491

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.

Authors:  K D Ramaiah; P K Das; P Vanamail; S P Pani
Journal:  Trop Med Int Health       Date:  2003-12       Impact factor: 2.622

2.  Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.

Authors:  B V Babu; S K Kar
Journal:  Trop Med Int Health       Date:  2004-06       Impact factor: 2.622

3.  Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach.

Authors:  Margaret Fraser; George Taleo; Fasihah Taleo; James Yaviong; Morris Amos; Mark Babu; Morris Kalkoa
Journal:  Am J Trop Med Hyg       Date:  2005-10       Impact factor: 2.345

4.  Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment.

Authors:  Reda M R Ramzy; Maged El Setouhy; Hanan Helmy; Ehab S Ahmed; Khaled M Abd Elaziz; Hoda A Farid; William D Shannon; Gary J Weil
Journal:  Lancet       Date:  2006-03-25       Impact factor: 79.321

Review 5.  Lymphatic filariasis: Treatment, control and elimination.

Authors:  Eric A Ottesen
Journal:  Adv Parasitol       Date:  2006       Impact factor: 3.870

6.  Factors associated with participation in a campaign of mass treatment against lymphatic filariasis, in Leogane, Haiti.

Authors:  E Mathieu; P J Lammie; J Radday; M J Beach; T Streit; J Wendt; D G Addiss
Journal:  Ann Trop Med Parasitol       Date:  2004-10

7.  Participation in three consecutive mass drug administrations in Leogane, Haiti.

Authors:  Els Mathieu; Abdel N Direny; Madsen Beau de Rochars; Thomas G Streit; David G Addiss; Patrick J Lammie
Journal:  Trop Med Int Health       Date:  2006-06       Impact factor: 2.622

8.  Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs.

Authors:  Paul T Cantey; Jonathan Rout; Grace Rao; John Williamson; LeAnne M Fox
Journal:  PLoS Negl Trop Dis       Date:  2010-06-29

9.  Knowledge and beliefs about elephantiasis and hydrocele of lymphatic filariasis and some socio-demographic determinants in an endemic community of Eastern India.

Authors:  B V Babu; R K Hazra; G P Chhotray; K Satyanarayana
Journal:  Public Health       Date:  2004-03       Impact factor: 2.427

10.  Defining the cost of the Egyptian lymphatic filariasis elimination programme.

Authors:  Reda M R Ramzy; Ann S Goldman; Hussein A Kamal
Journal:  Filaria J       Date:  2005-08-02
  10 in total
  5 in total

1.  Molecular xenomonitoring (MX) and transmission assessment survey (TAS) of lymphatic filariasis elimination in two villages, Menoufyia Governorate, Egypt.

Authors:  M A Moustafa; M M I Salamah; H S Thabet; R A Tawfik; M M Mehrez; D M Hamdy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-02       Impact factor: 3.267

2.  Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.

Authors:  Alison Krentel; Rita Damayanti; Christiana Rialine Titaley; Nugroho Suharno; Mark Bradley; Timothy Lynam
Journal:  PLoS Negl Trop Dis       Date:  2016-11-03

3.  Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis.

Authors:  Britt J Andersen; Jessica Kumar; Kurt Curtis; Nelly Sanuku; Samson Satofan; Christopher L King; Peter U Fischer; Gary J Weil
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

Review 4.  Factors Associated with the Acceptability of Mass Drug Administration for Filariasis: A Systematic Review.

Authors:  Ahmad Farid Nazmi Abdul Halim; Dzulfitree Ahmad; Jane Ling Miaw Yn; Noor Azreen Masdor; Nurfatehar Ramly; Rahayu Othman; Thinakaran Kandayah; Mohd Rohaizat Hassan; Rahmat Dapari
Journal:  Int J Environ Res Public Health       Date:  2022-10-10       Impact factor: 4.614

Review 5.  Elimination of lymphatic filariasis: current perspectives on mass drug administration.

Authors:  John O Gyapong; Irene O Owusu; Frances B da-Costa Vroom; Ernest O Mensah; Margaret Gyapong
Journal:  Res Rep Trop Med       Date:  2018-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.